Sai Life
Sai Life Q1 FY26 Results & Concall Highlights: Capex ₹700 Cr
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Sai Life Sciences anticipates sustained growth driven by both existing and late-stage pipeline products with strong visibility from client demand (Page 15). Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth).
From Sai Life's Q1 FY26 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Sai Life Sciences anticipates sustained growth driven by both existing and late-stage pipeline products with strong visibility from client demand (Page 15).
- The company targets a 3-5 year CAGR around 15% across combined CRO and CDMO businesses (Page 11).
- Manufacturing capacity is expected to increase by approximately 80-90% by FY'27, supporting volume growth (Page 12, 11).
- Process R&D capacity is planned to nearly double by next year, enhancing support for clinical and commercial supply programs (Page 3, 8).
- Growth will be fueled by new modalities like oligonucleotides (near commercial), ADCs (late-phase assets), peptides (early clinical stage), and lipids (Page 9).
- No major impact is expected from reshoring or US capacity additions on intermediates and APIs supplied by Sai (Page 15).
- Business scaling and operating leverage are expected to improve margins toward 28%-30% (Page 4).
- Overall, growth is driven by deepening client partnerships, increased scientific depth, and capacity expansions to meet evolving needs (Page 4, 15).
Profitability & Margins
See what Sai Life said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Sai Life Sciences is undertaking a large CAPEX of ₹700 crores for FY26.
- This CAPEX is based on strong visibility from existing products scaling up and late-stage pipeline projects plus clinical inquiries and collaborations.
- ₹700 crores CAPEX is for the current year, with CAPEX likely continuing next year though numbers are not finalized.
- The CAPEX covers manufacturing expansions including new production blocks (totaling around 450 KL capacity by H2 FY27) and Discovery capacity additions.
- Research & Development (R&D) capacity is doubling by next year, and manufacturing capacity is expected to increase by about 80%-90% by FY27.
- New capacity additions include 91 KL commissioned recently, 200 KL by Q3 FY27, and 450 KL expected by H2 FY27.
- Expansion also includes adding peptides and early-phase formulation capabilities.
- The company is diversifying its footprint to reduce concentration risk.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sai Life said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has better visibility on order book now compared to the past, with increased confidence about utilization levels going forward.
- There is no specific mention of a quantified current order book value in the transcript.
- The capacity buildup is now more aligned with anticipated orders over the next 12-24 months, indicating strong client commitments.
- Late-stage pipeline visibility is strong, supported by existing forecasts, clinical inquiries, and ongoing development programs with large pharma.
- The company continues to onboard new large pharma customers and deepen relationships, enhancing order book quality.
- The CDMO business remains lumpy and volatile quarter-on-quarter, but growth is driven by both commercialized and existing molecules.
- Despite volatility, no one-offs or stock build-ups affecting order flow were reported in Q1 FY'26.
Sai Life — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹602 Cr, net profit ₹104 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sai Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Cipla Ltd (Q1 FY26)
One Africa business grew 11% YoY, with continued focus on expansion. Key concall takeaways from Cipla's Q1 FY26 earnings call — and how it ranks against sector…
- Anthem Biosciences Ltd (Q1 FY26)
Capacity utilization in custom synthesis is around 70%, with expansions ongoing, indicating potential for further revenue growth. Key concall takeaways from…
- Senores Pharmaceuticals Ltd (Q1 FY26)
. Key concall takeaways from Senores Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Akums Drugs & Pharmaceuticals Ltd (Q1 FY26)
300 crores linked to European markets. Key concall takeaways from Akums Drugs & Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
Frequently Asked Questions
What were Sai Life Q1 FY26 results?
Sai Life Sciences anticipates sustained growth driven by both existing and late-stage pipeline products with strong visibility from client demand (Page 15). Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth).
What is Sai Life share price analysis?
Sai Life currently shows a neutral. The stock trades at a P/E of 84.1 with a market cap of ₹30,940 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sai Life planning capital expenditure?
Sai Life Sciences is undertaking a large CAPEX of ₹700 crores for FY26.
Keep Sai Life on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.